Phibro Animal Health Corporation announced a leadership transition to support continued growth and strategic direction.
Jack Bendheim to become Executive Chairman and Daniel Bendheim named Chief Executive Officer and President.
The transition is effective July 1, 2026, with Jack Bendheim shifting to a new role and Daniel Bendheim taking on the CEO and President positions.
Transition Details
Jack Bendheim moves to Executive Chairman role, while Daniel Bendheim becomes CEO and President.
Jack Bendheim's Legacy
Jack Bendheim led Phibro through global expansion, portfolio growth, and operational transformation.
Dani Bendheim's Experience
Dani Bendheim has extensive experience across Phibro's global operations and proven leadership track record within the company.
- The leadership transition aims to guide Phibro Animal Health Corporation into its next chapter of growth and development.
- The Board of Directors expressed unanimous support for the transition, showing confidence in the leadership team's capacity to execute the growth strategy.
Phibro's transition reflects strategic planning ensuring continuity and innovation in alignment with the company's values and commitment to animal health.